Year archive

Apontis Pharma AG — 2023 filings

All 20 regulatory filings released by Apontis Pharma AG (APPH) in 2023, sourced directly from the official regulator.

20 Filings

2023 Period

2023 filings (20)

Filing	Released	Lang
APONTIS PHARMA presents details of the restructuring and efficiency program Nine-month figures for 2023 and new sales and earnings forecast for 2023 published Earnings Release 9M 2023	2023-11-09	English
APONTIS PHARMA AG with new forecast 2023 and details on announced restructuring program Earnings Release 9M 2023	2023-11-08	English
APONTIS PHARMA confirms preliminary figures H1 2023 sales and earnings decline Earnings Release H1 2023	2023-08-10	English
Half-yearly financial statements 2023 Interim / Quarterly Report H2 2023	2023-08-10	English
APONTIS PHARMA: Co-promotion contract with AstraZeneca not to be continued in 2024 Regulatory Filings	2023-07-31	English
APONTIS PHARMA AG withdraws forecast for fiscal year 2023 and medium-term planning for 2026 Preparation of program to increase operating performance and efficiency launched Earnings Release H1 2023	2023-07-27	English
APONTIS PHARMA AG withdraws forecast for fiscal year 2023 and medium-term planning for 2026 Earnings Release H1 2023	2023-07-27	English
APONTIS PHARMA: CEO Karlheinz Gast resigns for personal reasons - Bruno Wohlschlegel takes over as successor Board/Management Information	2023-07-10	English
APONTIS PHARMA AG: CEO Karlheinz Gast resigns from office for personal reasons Board/Management Information	2023-07-10	English
APONTIS PHARMA launches Single Pill Finder and distribution of Single Pill Rosazimib - First of three launches in 2023 Regulatory Filings	2023-06-29	English
APONTIS PHARMA in Q1 2023 records decline in sales and earnings as expected 2023 as a transition year in focusing on Single Pills Earnings Release Q1 2023	2023-05-09	English
APONTIS PHARMA: Keeping up high pace in expansion of Single Pill portfolio - New development partnership with Zentiva Group for another Single Pill with EU-wide intellectual property rights Regulatory Filings	2023-05-08	English
APONTIS PHARMA AG: Silke Reineke, buy Director's Dealing	2023-05-05	English
APONTIS PHARMA AG adjusts forecast for fiscal year 2023 Regulatory Filings	2023-05-02	English
APONTIS PHARMA with first in-licensing of a Single Pill with two active ingredients for the primary prophylaxis of cardiovascular events - market launch already planned for early 2024 Regulatory Filings	2023-04-27	English
APONTIS PHARMA: New development partnership with Midas Pharma Expansion of Single Pill portfolio with EU-wide property rights opens up additional revenue potential M&A Activity	2023-04-12	English
Annual financial statements 2022 Annual Report FY 2022	2023-03-30	German
APONTIS PHARMA with successful financial year 2022: Revenue and EBITDA forecast slightly exceeded according to preliminary calculations Earnings Release FY 2022	2023-03-09	English
APONTIS PHARMA accelerates expansion of Single Pill portfolio with second of three in-licensing deals planned for 2023 Regulatory Filings	2023-02-14	English
APONTIS PHARMA extends portfolio for the treatment of hypertension and hyperlipidemia by in-licensing a new Single Pill Regulatory Filings	2023-01-31	English